Drugs / Actinomycin D
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04625907 | Sep 2020 → Jun 2030 expected | rhabdomyosarcoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06020755 | Dec 2024 → Aug 2025 overdue | gestational trophoblastic neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04817956 | Apr 2021 → Mar 2040 expected | metastatic malignant neoplasm | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04388839 | Dec 2020 → Aug 2026 overdue | rhabdomyosarcoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01782339 | May 2012 → May 2021 | germ cell tumor | Barts & The London NHS Trust | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00491946 | Jun 2004 → ? | cancer | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06028672 | Sep 2023 → Aug 2025 overdue | gestational trophoblastic neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 2 | NCT06699472 Background | Oct 2024 → Sep 2026 overdue | Ewing sarcoma, chemotherapy-induced toxicity | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05139095 Background | Jan 2022 → Dec 2026 expected | gestational trophoblastic neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT00643565 Background | Jul 2008 → May 2015 | sarcoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT03669783 Comparator | Feb 2023 → Oct 2028 expected | childhood kidney neoplasm | Assistance Publique Hopitaux De Marseille | Recruiting | No outcome recorded |
| Phase 3 | NCT04756713 Comparator | Feb 2021 → Dec 2024 | gestational trophoblastic neoplasm, hydatidiform mole | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02639650 Comparator | Mar 2016 → Mar 2024 | gestational trophoblastic neoplasm | Weiguo Lv | Unknown | No outcome recorded |
| — | NCT00541411 Background | Jun 2003 → Jun 2013 | Ewing sarcoma | King Faisal Specialist Hospital & Research Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Actinomycin-D | “In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days.” NCT04756713 ↗14“patients with metastatic RMS received four cycles of ifosfamide, vincristine, and actinomycin D (IVA) plus doxorubicin” PMID 35709412 ↗ Jun 2022 “Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg” NCT01782339 ↗ “etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine, alternate weekly” NCT05139095 ↗ “1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5” NCT03669783 ↗ “replace it with actinomycin D 1.25mg/m2” NCT06699472 ↗ “treatment Actinomycin-D” NCT03669783 ↗ “Actinomycin D” NCT04817956 ↗ |
| Known as | Act-D | “In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days.” NCT04756713 ↗ |
| Route | Intravenous | “iv bolus” NCT03669783 ↗ |